Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin receptor antagonists.

Joel B Nelson1

  • 1Department of Urology, University of Pittsburgh School of Medicine, 5200 Centre Ave, Suite 209, Pittsburgh, PA 15232, USA. nelsonjb@upmc.edu

World Journal of Urology
|January 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, a mitochondrial protein essential for efficient function of the electron transport chain.

The Prostate·2024
Same author

Association of Routine Preoperative Frailty Assessment With 1-Year Postoperative Mortality.

JAMA surgery·2023
Same author

Administration of 3% Sodium Chloride and Local Infusion Reactions.

Children (Basel, Switzerland)·2022
Same author

(+)-JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist.

Molecular cancer therapeutics·2022
Same author

Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.

HGG advances·2022
Same author

SafeNET: Initial development and validation of a real-time tool for predicting mortality risk at the time of hospital transfer to a higher level of care.

PloS one·2021
Same journal

Tranexamic acid in endoscopic enucleation of the prostate: does surgeon preference confound the protective effect?

World journal of urology·2026
Same journal

Holmium laser enucleation of the prostate as salvage therapy for benign prostatic obstruction after multiple prior surgical interventions.

World journal of urology·2026
Same journal

Testing reliability of pubourethral ligament hemostat forceps support test for diagnosis of stress incontinence.

World journal of urology·2026
Same journal

Safety and efficacy of different surgical approaches in single-port robot-assisted radical prostatectomy based on propensity score matching analysis.

World journal of urology·2026
Same journal

Intrarenal pressure and clinical outcomes during suction-assisted versus conventional percutaneous nephrolithotomy: a systematic review and meta-analysis.

World journal of urology·2026
Same journal

AI-driven model for early failure prediction after HIFU integrating immediate post-ablation ultrasound and clinical data.

World journal of urology·2026
See all related articles

New therapies targeting the endothelin axis show promise for hormone refractory prostate cancer. Atrasentan, an endothelin receptor A antagonist, delayed disease progression in clinical trials, potentially managing advanced prostate cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Hormone refractory prostate cancer (HRPC) progression is difficult to manage.
  • Novel therapeutic targets are needed for HRPC.
  • The endothelin axis is implicated in prostate cancer progression.

Purpose of the Study:

  • To review the role of the endothelin axis in prostate cancer.
  • To discuss preclinical data supporting endothelin receptor antagonists.
  • To present clinical trial findings for atrasentan in HRPC.

Main Methods:

  • Literature review of endothelin axis in cancer.
  • Analysis of preclinical studies on endothelin signaling.
  • Summary of Phase II and III clinical trial data for atrasentan.

Related Experiment Videos

Main Results:

  • The endothelin axis is a viable therapeutic target in prostate cancer.
  • Atrasentan, an endothelin receptor A (ET(A)) antagonist, demonstrated efficacy.
  • Disease progression was delayed in some patients with advanced prostate cancer treated with atrasentan.
  • Atrasentan was well tolerated and is an oral agent.

Conclusions:

  • Targeting the endothelin axis, specifically ET(A) receptors, offers a new therapeutic strategy for HRPC.
  • Atrasentan shows potential to manage advanced prostate cancer, possibly converting it to a more chronic condition.
  • Further investigation into atrasentan and the endothelin axis is warranted for HRPC treatment.